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The finding that human epidermal growth factor 
(hEGF) and human transforming growth factor (hTGF) 
« hind with similar affinity to the human EGF receptor 
but differ in their affinity for the chicken EGF receptor 
was used as a model system to study ligand-receptor 
interaction of EGF receptor agonists. We previously 
constructed domain-exchange mutants of hEGF and 
hTGF« and found that the region COOH-terminal of the 
sixth cysteine residue in hTGF« is important for high 
affinity binding to the chicken EGF receptor (Kramer, 
K. II.* Lenferink, A* E. G., I jammer ts van Bueren-Koorn- 
neef, I.* van der Meer, A., van de Poll, M. L. M,, and van 
Zoelen, K. J. J. (1094) J. Biol. Che in, 209, 8708-8711). To 
analyze this domain in more detail, we now constructed 
four additional chimeras in which either the region be­
tween the sixth cysteine residue and the highly con­
served Leu-47 was exchanged or the region COOH-tor- 
minal of Leu-47, A mutant in which the latter region in 
hEGF was replaced by hTGF« (designated E6ET) 
showed intermediate binding affinity, whereas replace­
ment of the former region in hEGF by hTGF« was suffi­
cient to generate a mutant (designated E6TE) with a 
similar high affinity for the chicken EGF receptor as 
wild type hTGF«. Furthermore, a deletion mutant of 
hEGF lacking three COOH-terminal amino acids, 
KGF50, showed intermediate binding affinity for the 
chicken EGF receptor similar to E6ET, but upon addi­
tional deletions (EGF41) and EGF48), this initial gain in 
affinity was lost. A systematic analysis of the region 
between the sixth cysteine residue and Leu-47 showed 
that the low affinity of hEGF for the chicken EGF recep­
tor is mainly due to the presence of Arg-45. Replacement 
of the positively charged Arg-45 by Ala, the correspond­
ing amino acid in hTGF«, was sufficient to generate a 
mutant growth factor with high affinity for the chicken 
EGF receptor. This indicates that in hEGF Arg-45 may 
play an important role in receptor binding. A model is 
proposed in which positively charged amino acids close 
to or within the receptor recognition site of hEGF pro­
hibit high affinity binding to the chicken EGF receptor 
due to electrostatic repulsion of positively charged 
amino acids in the putative ligand binding domain of 
the chicken EGF receptor.
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Human epidermal growth (actor (hEGF)1 and human trans­
forming growth factor (hTGF) a belong to the same family of 
growth factors. They both bind with high affinity to the human 
EGF receptor, but hEGF has a 1.0-50-fold lower affinity for the 
chicken EGF receptor than hTGF« (1). All members of the EGF 
family are characterized by the presence of six identically 
spaced cysteine res id new, which form three intramolecular di­
sulfide bridges. Together with some highly conserved glycine 
residues they are essential for the correct three-dimensional 
structure of the growth factor and for high affinity binding to 
the EGF receptor (2-4). Several other amino acids in hEGF 
like Leu-47 (Leu-48 in hTGF«) and Arg-41 (Arg-42 in hTGF«)» 
which are not involved in maintaining structural integrity, 
have been shown to he crucial for high affinity binding to the 
EGF receptor, which suggests that they form part of the bind­
ing domain (5-9). The crystal structure of hEGF or hTGF« is 
not available, and most of the information on the structure of 
these growth factors has come from detailed Ui NMR studies. 
Based on the observation tha t amino acids surrounding the 
second cysteine residue are in close contact with amino acids 
near the sixth cysteine residue, it has been postulated th a t 
Tyr-18/L(3u-15/His-16 together with Arg-41/Gln«48/Leu-47 
form the binding site in hEGF (10—122), The exact region in­
volved in binding to the receptor is still not known, however, 
and this has hampered the design of receptor antagonists.
To gain more insight in the way hEGF and hTGF« bind to 
their receptor, we recently used the difference in binding affin­
ity of these growth factors for the chicken EGF receptor as a 
model system. A total of 10 hEGF/hTGF« chimeras were con­
structed in which regions bordered by the highly conserved 
cysteine residues were exchanged, and their relative binding 
affinity for the chicken EOF receptor was assessed (18). Intro­
duction of the region COOH-terminal of the sixth cysteine 
residue of hTGF« into hEGF appeared to be sufficient to confer 
high affinity binding characteristics to hEGF, and, in line with 
this, an exchange of the same region in hTGF« with the corre­
sponding hEGF sequence caused hTGF« to lose its high affinity 
for the chicken EGF receptor. These data indicate that the 
COOH-terminal region in EGF receptor agonists plays an im­
portant role in receptor binding. In a recent lH NMR study 
04), it has been shown tha t this region of hTGF« is flexible in 
the unbound molecule hut th a t its mobility is strongly reduced 
upon receptor binding, which emphasizes again the role of the 
COOH-terminal domain in re cep tor-ligand interaction.
In the present sLudy, we investigated in more detail which
1 The abbreviations tmed are: hKOK, human epidermal growth factor: 
MKCiF, mouse JOOF; hTGF, hum an transforming growth factor; UP- 
IIPLO, rcverse-phasc» high pressure liquid chromatography; DM KM, 
DnlbiiccoV modified Eagle’« medium; NOS, newborn calf serum; BKK,
iV,A/-bis(2-hydroxyothyl)-2-aminot;Ihunosulibnic acid.
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am ino  acids in  th e  C O O H -te rm in a l  d o m a in  a re  responsib le  for 
h ig h  a ffin ity  b in d in g  to  th e  ch ic k e n  E G F  recep tor. To do so, th e  
b in d in g  c h a ra c te r is t ic s  of a n  a d d it io n a l  7 hEGF/liTGFo: ex­
ch an g e  m u ta n ts  a n d  3 C O O H -te rm in a l  t ru n c a te d  forms of 
h E G F  w ere  in v e s t ig a te d . A s in g le  am in o  ac id  exchange, Arg-45 
to  Ala, w as  found  to  be su ffic ien t to  g e n e ra te  an  h E G F  m u ta n t  
w i th  h ig h  a ff in ity  for t h e  ch ick en  E G F  recep to r.
EXPERIMENTAL PROCEDURES
DNA Constructs-'The gene encoding the m ature 50-amino acid se­
quence of hum an TGF« was made as previously described (13). The 
synthetic gene for hum an EGF was obtained from British Biotechnol­
ogy (Oxford, United Kingdom). The genes were linked at the 5'-end to 
the sequence coding for the recognition sequence of the proteolytic 
enzyme factor X (Ile-Glu-Gly-Arg) (15). In former experiments (13), till 
constructs had been cloned into the pHomaI53 expression vector. Be­
cause in our hands a higher level of expression of biologically active 
protein was obtained using the pEZZ18 expression vector (Pharmacia, 
Uppsala, Sweden), the EcaRl-Sall fragments of pHemal53/FX/EGF 
and pHemal53/FX/TGFa were cloned into the corresponding sites of 
pEZZl8. In this way, the constructs encoding hEGF and hTGF« were 
placed in frame 3' of the sequence coding for the two synthetic IgG 
binding domains (so called Z domains) of pEZZl8. All further constructs 
were cloned into pEZZ18 using the Sail site at the 3 '-end and either the 
EcoRI site or the BamHl site (which lies 9 base pairs downstream of 
EcoRl) at the 5'-end.
For the construction of T6TE and T6ET (for definition, see Fig. 1. and 
“Results”), the gene coding for hTGF« was cleaved at the sixth cysteine 
codon by DmIII and at the 3 '-end by Sail, The gap was Oiled in using 
synthetic double-stranded oligonucleotides. For the construction of 
E6TE, hEGF was digested at the fourth cysteine codon by Sphl, and 
T6TE was cleaved at the sixth cysteinc codon by D ralll. The fragments 
were ligated to a double-stranded oligonucleotide spanning the region 
between the Sphl site and the DralU  site. To generate E6ET, the Sphl 
site and the Sail site of the hEGF construct were used, and the gap was 
filled in using two double-stranded oligonucleotides, DNA constructs 
that code for hEGF m utants truncated at the COOH-terminal end, 
EGF50, EGF49, and EGF48, were made by polymerase chain reaction 
using pEZZ/FX/EGF as a template. Three different antisense primers 
were designed such that the generated polymerase chain reaction prod­
ucts contained either the codon for Trp-50, Trp-49, or Lys-48 at Choir 
3 '-end followed by a stop codon and the Sail recognition site. For all 
constructs, the same sense primer was used, which annealed 5' of the 
Z2coRI site of pEZZ/FX/EGF. Polymerase chain reaction products of the 
correct length were isolated and cloned into the modified EcoRV site of 
pT7blue T (Novagen Inc., Madison, WI) and subsequently transferred to 
pEZZ18 by EeoTtl-Sall digestion. Point mutations in the hEGF gene 
were generated using the Altered Sites™  II in vitro mutagenesis sys­
tem (Promega). All pEZZ18 m utant constructs were verified by DNA 
sequencing.
Expression and Purification o f Growth Factors—Wild type and mu­
tan t growth factors were expressed as ZZ/FX/growth factor fusion pro­
tein in Escherichia eoli KS474, a degP protease-deficient mutant (a 
generous gift from Drs. K. L. Strauch and J. Beckwith, Harvard Uni­
versity) (see Ref. 16), Bacteria were grown in 2YTE (16 g of bactotryp- 
ton, 10 g of yeast, 8 g of NaCl/liter) a t  28 °C until an Am)0 of 1.5 was 
reached and the periplaamic proteins were isolated as described (.17). 
After purification on IgG-Sepharose (Pharmacia), the amount of fusion 
protein recovered was measured by a competitive enzyme-linked im­
munosorbent assay using biotin-labeled protein A (19). The fusion pro­
teins were digested by Factor XH coupled to CNBr-activated Sepharose, 
and the growth factors were purified by an additional run on IgG- 
Sepharose. Final purification was by RP-KPLC on a 15 x 0.39-cm 
Delta-Pale C lH column (Millipore). Elution was carried out with a linear 
gradient of CIi;lCN in 0.1% triiluoroacctate at a flow rate of 1 ml/min. 
The biological activity in the column fractions (1 ml) was assayed on 
HER-14 cells in a binding competition assay with Iyr,I-mEGF (see 
below).
Analysis of Fusion Proteins by SDS-Potyacryla.niide Gel Electro• 
phoresis and Western Blotting—Aliquots of 10 ¡jl\  of tin purified 
periplasm were analyzed by gel electrophoresis on a 12.5% SDS-poly- 
acrylamide gel in the absence or presence of 2% /3-morcaptoethanol as 
a reducing agent. Proteins were transferred to nitrocellulose, and the 
Western blots were probed with a rat-anti-goat antibody linked to 
horseradish peroxidase. Enzyme activity was detected by incubation 
with tetramotbylbenzidine/sodium dioctylsulibsuccinate/I-LOy in phos­
phate/citrate buffer (pH 5).
Cell Lmtv—NIHtfTM cells transfected with (he human KUF receptor 
(HER-14 cells, 400,000 receptors/cell} or the chicken KGF receptor 
(CER-109 cells, 50,000 receptors/cell) were a generous gift from Dr. J, 
Schlessinger (New York University), ( ’ells wore cultured in Dulhecco’s 
modified Eagle’s medium (DMIOM) supplemented wilh 10% newborn
calf serum (NOS).
v-r,LmEGF Binding Competition Assays- Mouse KGF (Bioproducts
for Science Inc., Indianapolis, IN) wan imliuuled using eu'/.ymohends
(Bio-Rad) to a specific activity of 500 (M/mmol ( IH). 11 KIM 4 cells were
grown to coniluency in gelatinized ¿M-well dishes ( 1.8 cm } and (vhR»
109 cells in 6-well dishes (9.8 cor), '^ ‘l-mEGF i \ ug/m) for 1U01M4 and
40 ng/ml for GER-109) and serial dilutions of uulubeled growth factors
w e r e  a d d e d  to th e  cells in DM KM c o n t a i n i n g  If» him IlKPKtt (pt  I 7.7)
and 10% NCS to inhibit nonspecific binding. After incubation for 2 h at
room temperature, cells wore washed twice wilh ice cold phosphate-
buffered saline, 0 .1% bovine serum albumin, and uuee with ice-cold
phosphate-buffered saline. The cells were incubated subsetjuently in 1%
Triton X400 for I h at room temperature prior to y -counting. Kxperi»
ments with HKU-H were performed in triplicate and with HKIMOO in
duplicate.
Mitof*miv As,s«y«~-‘1IKIM'1 cells were seeded in gelatinized IM-well 
dishes at a density of (50,000 cells/well in 1 nil ot DMKM. 10% N('S, 
After 24 h of incubation, the medium was replaced by tM) ml of I lam's
___ __ . . « - 1 ■ . I f i l l  ,  . * . i  i 1 *  I  w  % / i f
i l l  \K l  lYum lu vm w i VUUMUUIUK on mul n r /n  t|»n  u .o i, n u i»u,ri , u j i  /<v -
of I:,H|thyniidine was added in 0.1 ml of Hum's Fltf medium, lucorpo 
ration of the tracer into cellular DNA was determined *M h aftergrowth 
factor addition. For this, cell« were washed tw in’ with phosphate« 
buffered saline and incubated with methanol at room temperature. 
After If) min, the methanol was aspirated, and I lie cells were Ivsed in 1 
ml of 0,2 N NaOH for 110 miu at ¡17 ”(• as described tU7i. Ihulionetivify 
was determined by liquid scintillation counting, KxperimtMils were 
performed in duplicate,
H KS UI ;rs
Mutant Growth Factors In previous work < l*D, the COOK- 
terminal region in hTGFar was identified as an important do* 
main for high affinity binding ofhTGPu to the chicken KGF 
receptor, introduction of this region into hMJK generated a 
chimeric growth factor (designated KGTi with high affinity fur 
the chicken EGF receptor* whereas T0K, a ehiiuera with TGFu 
¡sequences NH.r termimd and KGK sequences ( ’()( Hbtrrininal 
of the sixth cysteine residue, has a low affinity. In the present 
study, the importance of specific amino acids within the linear 
COOH-terminai domain was investigated in more detail. First, 
EGF/TGF« chimeras wore constructed in which either the re­
gion between the sixth cysteine residue and the highly con­
served Lou-47 (Leu-48 in hTGFa) or the region (■<Kill-termi­
nal of Lou-47 was exchanged, In this way, lour K( tl’VT( rFrr 
exchange mutants wore generated designated KISKT. KiYVK, 
T6ET, and T(jTE (Fig. I). Next, individual amino acids in the 
region between the sixth cysteine residue and Leu-47 in hKtrF 
were systematically exchanged with the corresponding amino 
acids in hTGFa, making the hftCF point mutants Y44H.
and R 4 5 A (Fig. I). In addition, hKGF deletion mutants F.GPftO, 
EGF49, and I.0GF48 were constructed to evaluate ( Ik* role of the 
relatively long COOII-fermirud tail of hKGF (KWWKLRi rrr* 
m s  the much shorter tail of hTOFo lLAi.
Expression and Puri/lcutinn of Hcvomhitutnl (¡rotrfh l*\tv* 
¿ors—The expression of ZZ/FX/growth laetor fusion protein in 
the periplasm was analyzed by ttl)S“pnlyncryhinnde gel elecu 
trophoresis and Western blotting, and the total amount oflgC 
binding activity in the periplasm was measured by a competi­
tive enzyme-linked immunosorbent assay i MH. The levels of
&
expression of wild type and mutant growth (actors appeared to 
be similar on Western blot as shown in Fig. II for wild type 
hEGF and the hEGF point mutants Q43K, Y441I, and K45A. 
The total amount of IgG binding activity in the periplasm 
langed from 5 to 10 pg/ml using protein A tSigma* as a stand- 
ard. Additional bands oi higher molecular weight wore present
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Elution way carried out with a linear gradient of CH.,ON in 0.1% 
trifluoroaeetate a t  a ilow rate  of 1 ml/min. Biological activity present in 
the column fraction« was determined in a binding competition assay
wiLh ,aRI-mEGF.
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3 ft
Ki<;. 2. Id en tif ica tio n  of XZ/FX/growth fac to r fusion p ro te in s  
by SD S-polynerylnm ide gel e lee trophoresis  and W estern  b lo t­
ting, Aliquots of 10 /d of impuriilod periplasm were run on a 12,5% 
Sl)S«polyaorylamidi' gol undor non-n*ducing i/\) or reducing (B) condi­
tion«, P r o t o i n s  w(M'4i LranMleiTod to nitrocolluliiHO, and tho Wontem blotH 
wotv pnibcd with rat-anti-goat antibody linkod to hornoradiHh poroxi- 
da«o: wild Lypt* liKt *K, lanox 1 and 6*; Q'iiiE, lanes 2 and 7; Y44H, lanon 
!i and IM5A, hi nr# 4 and f); control poripianm (pEZZlH w i t h o u t  
insort), lu/ic !».
on WoHtorn bloL hut dimippfmml under reducing conditions, 
indicating tho pronunce of a snudi amount of (inactivo) multi- 
inoric forniH of tho growth factor fusion pi*otoins. Ono uniden- 
tiilod )>nnd of 2d kDa, also prosonl in control periplasm 
(plW/ZAH  without insorU, is thought Lo he due to nonspecific 
binding of IgU-peroxidnHo. Wild type and mutant growth fac­
tors worn purified uh described under “Experimental Proce­
dures,n and the presence of fusion protein or growth factor 
activity nflor ouch purification stop was monitored by Western 
blotting, protein A enzyme-linked immunosorbent assay, 
and/or ^ ’l-mKGK binding competition assay. The growth fac­
tors were finally purified hy UP-HPLO using a linear gradient 
of CH;,(!N in 0, 1% IrifluorouceUite (Pig. 3A). Fractions were 
analyzed for biological activity in a binding competition a*ssay 
with 1linI-mI£(lF (Fig. lUi). In general, ono major (peak I) and
two minor (peak Ila/b) biologically active products eluted be­
tween 25 and 35% CH:{CN. When peak I and peak Ila/b were 
assayed separately (as was done for EGF50 and R4-5A), no 
differences were detected in their relative affinity for the 
chicken EGF receptor. With all other growth factors» peaks I 
and Ila/b were pooled. The identity of peaks I and IIo/b was not 
established, but it is assumed tha t the major peak represents 
“unmodified” growth factor, whereas the two minor peaks may 
represent chemically modified products or NI~L-terminally 
truncated forms (2 ). Truncations at the COOH-terminal end 
are less likely since none of the biologically active peaks iden­
tified in EGF50 coeluted with those of EGF49 or EGF48 on the 
RP-HPLC column. Degradation of EGF upon storage has been 
reported to involve oxidation of Mot-21, deamination of Asn-1 
and/or succinimido formation of Asp-11 (2, 20), Oxidation of 
Mot-21 and NH^-tcrminal deletions up to three amino acids 
does not significantly alter the biological activity of EGF (2), 
12f>I-mEGF Binding Competition Assays on HER-14 and  
CER-109—To determine tho binding affinity of tho mutant 
growth factors for the human EGF receptor, the total binding 
activity present under peak I and peak Ila/b was measured in 
a 12r,I“inEGF binding competition assay on HER-14 cells. Wild 
type mEGF (Bioproducts for Science Inc., Indianapolis, IN) was 
used as a standard, and the binding activity of the m utant 
growth factors was expressed as ng mEGF equivalents, The 
ratio between binding activity and the amount of protein rep-
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T a b l e  I
Binding affinities of hEG F mutants for the human EG F receptor
The ratio (R) between binding activity present under peaks I and 
Ila/b in the RP-HPLC chromatogram (ng mEGF equivalents) anti tho 
amount of protein represented by the peak area (mm2) was calculated 
for each m utant as well as for wild type mEGF (Bioproducts for Science 
Inc., Indianapolis, IN). The binding affinities of the m utant growth 
factors are expressed us percentage of wild type mEGF: R( mutant)/ 
R(wild type) X 100%.
100
h E G F  HpiieioH B in d in g  uiTimt.y
Wild type mEGI«’
EGF48
EGP4Ì)
EGF50 (puak I) 
EGFfiO (puuk Ila/li) 
Q43E 
Y44H
R45A (peak I)
R4fiA (peak Ila/b)
%  o f  ivild typv
100
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10«
10« 
i)0 
117 
00 
124
f  A1— s* »  .  •  m
resented by the peak area (absorption at 229 nm) was then 
calculated and comparod with tho ratio obtained with wild typo 
mEGF (Tablo I). For most of Lho m utant growth factoid tho 
binding affinity was ealculatod to ho close to Lho binding affin­
ity of wiEGF. Only tho affinity of EGF48 wan approximately 
2-iold lower. No Hiich data are availal)lo for tho exchange mu-
Lunls IWET, ISOTE, T(>ET, and TfiTK,
To determine tlu* differential binding characteristics (if the 
nuitant growth factors for the human and the chicken EGF 
receptors, all recombinant proteins were eventually calibrated 
to give the name 50% competition of !ar>I-mEGF binding to 
HER-L4 cells as wild type mEGF. An example of this is shown 
in Fig. 4 for the IiGF point m utants CJ43E, Y44H and R45A.
l H m \  EtiVE, T6KT. and  7Y>T/i^After calibration on 
HER-14 cells, the relative affinity of the m utan t growth factors 
for the chicken EGF receptor was, subsequently, compared 
with the affinity of wild type hTGF« and hEGF. Replacement 
of the region between the sixth cysteine residue and Leu-47 in 
hEGF for the corresponding region in hTGF« (E6TE), was 
sufficient to increase the affinity of hEGF for Lho chicken EGF 
receptor to the level of hTGF« (Fig. 5A), Interestingly, also the 
region GOOIi-terminal of Leu-47 influenced the affinity of 
hEGF for the chicken EGF receptor, Replacement of the rela­
tively long OOOlI-terminal tail in hEGF (KWWELR) for tho 
much shorter corresponding region in hTGF« (LA) resulting in 
EBET, caused n substantial increase in binding affinity for 
0ER-109 cells. The increase in affinity was even larger when 
this region was replaced in T 6E making T0ET; in contrasL, TfiE 
binds with a similar low affinity to the chicken EGF receptor as 
wild type hEGF (13).
EGF50, E( }F49, and EGF4H—One striking difference be­
tween hEGF and E(>ET is the relatively long GOOH-terminal 
tail (KWWELR) in hEGF as compared to a short tail (LA) in 
E(>ET (and hTGF«). To investigate whether this difference in 
tail length determines the difference in affinity between hEGF 
and EGET, COOH-termmally truncated for ms of hEGF wore 
prepared. Deletion of three COOH-terminal amino acids ELli 
of hEGF (EGF50) caused a 4-fold .increase in relative affinity 
for the chicken EGF receptor similar as seen with E 6ET. Upon 
additional deletion (EGF49 and EGF48), however, this initial 
gain in affinity was lost (Fig. 5B),
Q4tVC% Y44H, and 1145A ~~ Of all modifications of hEGF tested 
thus far in this study, replacement of tho region between the 
sixth cysteine residue and Lou-47 with the corresponding 
hTGF« sequence (E6TE) gave the largest increase in binding 
affinity. This region in hEGF differs from hTGF« only by three 
amino acids. To determine the individual role of these residues
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in high affinity binding to the chicken EGF receptor, each 
amino acid in this region in hEGF was successively exchanged 
with tho corresponding amino acid in hTGF«. In this way, the 
point mutants Q48E, Y44II, and R45A were generated. Muta­
tion of glutamine on position 4.3 to glutamate or mutation of 
tyrosine on position 44 to histidine hardly affected the relative 
affinity of hEGF for the chicken EGF receptor. However, ex­
changing arginine on position 45 in hEGF with alanine in 
hTGF« generated a hEGF mutant with a similar relative af­
finity for the chicken EGF receptor as hTGF« (Fig. 50). Also, 
the absolute affinity of R45A for the chicken EGF receptor will 
be close to hTGF« since its affinity for the human EGF receptor 
was estimated to be similar to wild type mEGF (Tablo I).
MitogvJiw Activity'—'['a test whether the mutant growth fac­
tors are biologically active, IIER-14 cells rather than CER409 
cells were used. We have noticed that wild type hEGF and 
hTGF« are equally mitogenic on GER-T09 cells, whereas clear 
differences were observed using primary chi clam adipocyte pre­
cursor cells.u The presence of endogenous mEGF receptors 
(3,000-10,000 receptors/cell) might cause a potentiation of the 
mitogenic response to growth factors that have a low affinity 
for the chicken EGF receptor but a high affinity for the mEGF 
receptor. Therefore, mitogenic assays on GER-109 cells are of 
limited value.
Because the binding affinity of all recombinant proteins was 
calibrated based on their ability to give 50% competition of 
llirT-mEGF binding to IIER-14 cells, any difference in relative 
mitogenic activity is most easily detected on the same cells. In 
Fig. 6 is shown that all growth factors were biologically active 
when tested for their ability Lo stimulate [;iH(thymidine incor­
poration into serum-starved HER-14 cells. Most of the mutant 
growth factors were similarly active as wild type hEGF or 
hTGF«, but one mutant, EGF48, induced a slightly higher
*
mitogenic response. The absolute affinity (if EGF48, however, 
was calculated to be — 2-fold lower than the affinity of the wild 
type growth factors (Table I). We therefore expect that EGF48 
will induce a similar mitogenic response as wild type hEGF 
when assayed on a protein basis. Loss of binding affinity with­
out a concomitant decrease in mitogenic activity has been re­
ported before by Walker et al. (5) for mEGF in which Leu-47
. As é  .
*' M, L. M. van de Poll, A. E. G. Lenferink, M, J. tL van Vugt, E. J. J. 
van Zoelen, and S. Butterwith, unpubliBhed results.
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wan calibrated baned on their ability to give 50% competition of U!r,I- 
mEGF binding to HICR-14 (see Fig. 4). Their relatives affinity for the 
chicken EGF receptor wan BubHequontly measured in a binding compe­
tition uHHuy on (TBR-109, The concentrations of the growth factor« are 
IhuH expressed an ng mEGF equivalents/ml. Representative curves of at 
leant three experiment« arc shown,
was mutated to Ala. In data to bo published elsewhere, wo will 
«how that, even on a protein basin, Home of the hEGF/hTGFc* 
chimeras constructed previously by us (13) are truly superago- 
n is tic for HER-14 when compared with wild type hEGF or
hTGFfl.
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of 10% NCS was 197,000 ± 6,000 cpm in A and 217,200 ± 3,000 cpm in 
B. Radioactivity incorporated in control ceil« (without growth factor 
addition) was 26,300 ± 1,800 cpm in A  and 61,500 ± 4,700 cpm in B. 
RepreHontative curvoH of at least th ree  expcn'iments ar« shown.
T.)ISGUSS10N
Mammalian EGF and TGF« bind with similar high aifinity 
to the human EGF receptor, but their affinity toward the 
chicken EGF rcceptor differs substantially (1). Human EGF 
has a 10-50-fold lower affinity for the chicken EGF receptor 
than human TGF«, and the affinity of mouse EGF is ~-5-fold 
lower than of hum an EGF (1, 13). We have previously used the 
differential binding characteristies of hEGF and hTGFa as a 
model to study ligand-receptor interactions (13). A total of 10 
chimeras of hEGF and hTGFtv were constructed, and it was 
found th a t chimeras with hTGFfv sequences OQOH-termmal of 
the sixth cysteine residue all had a similar high affinity for the 
avian EGF receptor as wild type hTGFVv, whereas those having 
hEGF sequences in this region showed EGF-like binding char­
acteristics* This indicates the importance of the CO OH-termi­
nal domain in discriminating between hEGF and hTGF«.
To identify amino acids involved in high affinity binding to 
the EGF receptor, a detailed analysis of the GOOIi-terminal 
domain of hEGF was made in the present study. Here, we show 
that the low affinity of hum an EGF for the avian EGF receptor 
is mainly due to the presence of arginine on position 45. Re-
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placement of the positively charged Arg-45 for alanine, the 
corresponding amino acid in hTGFa, was sufficient to generate 
a hEGF m utant with high affinity for the chicken EGF recep­
tor. Thus far, point mutation studies of the carboxyl-terminal 
region of hEGF and hTGFa have focused mainly on the highly 
conserved Asp-46 and Leu-47 (Asp-47 and Leu-48 in hTGF«). 
Leu-47 and (less stringently) Asp-46 have been shown to be 
crucial for receptor binding and activation (5, 7, 9 ,12). By using 
a domain exchange strategy, however, a systematic survey of 
the importance of non-conserved amino acids can be made. The 
present Finding tha t Arg-45 discriminates between hEGF and 
hTGF« with respect to their affinity for the chicken EGF re­
ceptor, implicates tha t this amino acid lies close to or forms 
part of the receptor recognition site.
Lax et al. (21) analyzed the differential binding characteris­
tics of the human and chicken EGF receptor using a domain- 
exchange strategy, and they demonstrated th a t domain III of 
the EGF receptor extracellular domain is most important for 
ligand recognition. Within this region the sequence between 
amino acids 351 and 364 was found to be the epitope recognized 
by ligand-competitive monoclonal antibodies (22), The partici­
pation of this epitope in the formation of a ligand binding .site, 
however, was recently questioned since exchange of this region 
in the human EGF receptor for the corresponding sequence in 
the chicken EGF receptor did not alter the affinity of mouse 
EGF or human TGF« for the receptor (23). On the other hand, 
one might expect that the epitope recognized by an antibody 
that competes with the natural ligand for binding to the recep­
tor lies close to the ligand binding site of the receptor. Imme­
diately COOH-terminal of the epitope two lysine residues are 
found in the chicken EGF receptor tha t are not conserved in the 
human EGF receptor (24), For one of these lysine residues, a 
conservative replacement (Arg) is found in the murine EGF 
receptor; this amino acid is, therefore, less likely to clittcrimi» 
nato between the chicken and the mammalian EGF receptor. 
The second lysine residue, however, is only found in the 
cl lie ken EGF receptor, whereas in the hum an EGF receptor 
this positively charged amino acid is replaced by a negatively 
charged glutamate. We hypothesize tha t the lysine residue on 
position 367 in the chicken EGF receptor lies close to or forms 
part of the ligand binding domain and that the positively 
charged Arg-45 in the putative receptor recognition site of 
hEGF prohibits the interaction of hEGF with the chicken EGF 
receptor due to electrostatic repulsion.
Other positively charged amino acids in hEGF that might 
interfere with ligand-receptor interaction, are Lys-48 and 
Arg-5 3 in the carboxyl-terminal tail of hEGF. Replacement of 
this region in hEGF (KWWELR) for the corresponding un­
charged sequence in hTGF« (LA), making E6ET, caused an 
increase in binding affinity. A similar improvement of binding 
affinity was found upon truncation of the carboxyl-terminal 
tripeptide ELR (EGF50) removing Arg-53 as the COOH-tormi- 
nal amino acid. Additional deletion of Trp-50, however, re­
sulted in a decrease in affinity for the chicken EGF receptor. 
Besides a difference in charge distribution, there is also a 
difference between hEGF and hTGFa in conformation of the 
CO Oil-terminal tail. In hEGF, this region adopts an «-helix 
conformation involving Lcu-47-Glu-51, whereas in hTGFa the 
COOH-terminal dipeptide is flexible in solution and lacks a 
defined structure (10, 14, 25). The «-helix in hEGF has an 
amphipatic character with Lys-48 and Glu-51 on the hydro­
philic site and Leu-47/Trp-B0 and Trp-49/Leu-52 on the hydro- 
phobic site. Iji addition, Trp-50 interacts with other hydropho­
bic amino acids in the pi’otein such as Val-34 and Tyr-37 (10). 
One might speculate that in EGF50 the carboxyl-terminal tail
can still adopt an «-helix conformation, which is stabilized by 
hydrogen bond formation between Leu-47 and Trp-50 as well as 
by VanderWaals interactions between Trp-50 and other hydro- 
phobic side chains. In contrast to EGF50, no «-helix structure 
will be formed in EGF49 or EGF48. The relatively high binding 
affinity of EGF50 for the chicken EGF receptor suggests that 
«-helix formation of the carboxyl-terminal tail of hEGF will 
prevent the positively charged Lys48 from interfering with 
ligand-receptor interaction, whereas it does interfere in the 
case of EGF49 and EGF48.
In conclusion, we propose a model in which positively 
charged amino acids close to or within the putative receptor 
recognition site of hEGF (Arg-45 and to a lesser extent Lys-48 
and Arg-53) prohibit high affinity binding to the chicken EGF 
receptor due to electrostatic repulsion of positive charges in or 
near the putative binding domain of this receptor. Comparing 
the carboxyl-terminal sequences of EGF receptor agonists of 
different origin, the proposed model would predict that EGF 
derived from human, mouse, or rat will have a low affinity for 
the avian EGF receptor, whereas human and rat TGF« but also 
EGF from guinea pig will have a high affinity for the avian 
EGF receptor.
In addition to amino acids in the COOH-terminal domain, 
residues in other domains are thought to form part of the 
binding domain in EGF and TGF«. NMR studies have 
shown, for instance, that amino acids near the sixth cysteine 
residue are in close contact with residues surrounding the 
second cysteine residue (1.0)* and in a recent study Richter et aL 
(26) hypothesized that amino acids in the B-loop /3-sheet deter­
mine the difference in binding affinity between human EGF 
and mouse EGF for the chicken EGF receptor. Perhaps EGF 
receptor agonists contain two distinct binding domains that 
each can bind one receptor monomer similar as seen for the 
interaction of human growth hormone with its receptor (28). 
Data in favor of this model have been discussed previously by 
Gullick (29). Additional studies will bo necessary, however, to 
increase our understanding of the way EGF and TGF« interact 
with their receptor and to make the design of receptor antag­
onists feasible,
Acktwiufatltf w o n ts  — Wo aro g m lo fu l  to Dr. T. «J. f to im m d mid 
J ,  J ,  T. M. Houvol (D e p a r tm e n t  of E x p c r im o n tn l  a n d  C hem ica l E ndo ­
crinology, U n ivers i ty  .Honpital, St. R udboud, T h e  NothorlandH) for the  
genorotiH nupply  of u,r’I-mHQF,
IIKKEKENCIKH
1. Lux, I., Johnmm, A., ITowk, U., Hup, J,. Ballot, R ,  Winklttr, M>, Ullrich, A.,
Vuunttlrom, H,, SotiluHHin^or, */., and Givol, I). (1988) MW, ('vll. Hiol. 8, 
1970 - 1U78
2. ClnrpunU»!*, (},, and Wahl, M. I. (1991) in Vv.pt ith Growth Factors tout
Tht'ir Rwoplorn (Sporn, ML H., and RohorlH, A. B,, «dm Vol. I. pp. iiSJ-171, 
Springr-Vm'lai; Now York Inc., No.w York 
tt. PHtfonl, ft. A., and L'inoiiU!, N. R, (1992) Vroft. Growth Factor Hon, 4, 1-24 
<1. Violaml, B. N., Tnu, «J. S., Vi noyard, U. 0,, Siutfel, N. It., »Smith, 0. 10., Pyla, V. 
P., Zohd, J. R , Torn», I*. O., and Kolodzioj, K. W. (1991) lot. J . Vvpt, Vrotvin 
ltw, 37, 4<i:M(17
5» Walker, R , Nice, 10., Pubri, L , May, R  »1., Liu, »J., Wu, U., Kdu'ratfn, 11. A., and
HurgoHH, A. W. (1 M)U) ¡}iocfu>nttetry ‘¿i>t IWWfi-iOiMO
(i. MntHunami, R. K„ Oarnpion, S. R., Niyogi, S. K.r and Htovoim, A, (1990) FKItfi 
U'.tt. 204, 105-108
7. Luzar, R ,  Walanabo, S., Dalton, S., and Sporn, M. B. Uf)88) Jl/n/. Cvll. Hiol. 8,
1247-1252
8. IOnglor, P. A., Monldiono, G. T., and Niyotfi, K. (1990) FKHti ¡A'(t, 271,
47-fi0
9. Campion, H. K., Tadaki, I)> K,, and Niyotfi, S. K. U992) J .  (.V//. Hiovhnn. 50,
¡15-42
10. Hommul, U., H arvey ,T. S., PriHColl, 1*. (*,, and Oampbtill, I. P. (11)92) *ƒ. Mot.
Ilbl. 227, 271-282
11. Richter, A., Conlan, J. W., Ward, M. 10., Chumburlin, S. G., Alexander, P.,
Kichnrdtf, N. Cl. J., and Davies, P. 10. (1992) iiiov.hcmtalry ¡11, 9JVl(i-i)nn4
12. Field, J. A,, Reid, U. II., Rio man, P. J., Page* Kline, 'P., Satin*, G., GriUtf, R. (».,
and AhKuno, M. A. (1992) 7Uochvm. J. 28«, 91-98 
1H. Kramer, R. H., Lonferink, A. R. G., hamtncrlH van Buereu-Kaommiol', van 
dor Moor, A., van do Poll, M. L. M., and van Zoulen, 10. J. J. (UKM),/. Hiol. 
Chctn. 200, H7OH-8711 
Id. Hoyt, P. W., Markina, R. N., Pobunnci, M. T., O’Gonnor-MeCourt, M., and
An EGF Mutant with High Affinity for the Avian EGF Receptor 2 2 3 4 3
Syken, B. D. (1994) Biochemistry 33, 1.{5283-15292
15. Nagai, K., and Thoger«en, C. (1987) Methods Etizymal. 153, 461-481
16. Strauch, K. L., Johnson, K., and Back with, J. (1989) J. Bacterial. 171,
2 i m -2 690
17. NilsHon, B.t and Abrahmaen, L. (1990) Methods Enzymal. 185, 144-161
18. Kionhuia, C, B. M., Houvel, J. J. T. M., Ruhb, II, A., Swinkals, L. M. J .  W.,
Foekcmn, J, A., and Benraad, T. J. (1.991) Clin. Chv.m. 37, 1749-1755
19. Van Zoolun, E. J. J,, Kruinor, R. II., Van Reen, M. M, M., Veerkamp, J. II., and
Rohn, II. A. (1993) Biochemistry 32, «275-6280
20. Sendorol'f, R. I., Wootton, S. C.t Doctor, A. M., Chon, T. M., Giordan!, A. B.,
Julian, T. N., and Radubnugh, G. W. (1994) Pharm. Hex, (NY) 11,1712-1720
21. Lax, I., BelloL, F., Howk, R., Ullrich, A., Givol, D., and SchloHHinger, J. (1989)
UMBO J. 8, 421“ 427
22. Wu, I)., Wang, L., Sato, G. H.. Wc;hL, K, A., Harri«, W. R., Orubb, J, W., and
Sato, J .  D. (1989) J ,  Biol, Cham. 264, 17469-17475
23. Brown, P. M., Dcbanno, M. T., Grothe, S., Bergamu, D., Caron, M., Kay, C., and
O’Connor-McCourt, M. D. (1994) Ear. J. Biwham. 225, 223-233
24. Avivi, A., Lax, I., Ullrich, A., Sohle BHinger, J .,  Givol, I)., und Morse, B. (1991)
Oncogene 6, 673-676
25. Gnllay, J . ,  Vincent, M., De la Sierra, I. M. L., Alvarez, J., Ubieta, R., Madruzo,
J., and Padron, G. (1.993) ICur. J. Biochum, 211, 213-219
26. Richter, A., Drummond, D. R., MacGarvie, J .,  Fucklicombo, S. M., Chamberlin,
S. G., and  Davies, 1). E. (1995) J ,  Biol, Chcm. 270, 16.12-1616
27. Van Zoelen, E. J, J., Van OoHlwaard, T. M. J .,  Van der Snag, P. T M and Do Laut,
S. E. (1.985) J . Cell. Physiol 123, 151-160
28. Fuh, G., Cunningham, B. C., Fukuimga, II., N agata , S., Goeddel, D. V., and
Wells, J .  A. (1992) Science 256, 1677-1680
29. Gullick, W. J. (1994) Ear. ,ƒ. Cancer 30, 2186
